
    
      This proposal aims to demonstrate the superiority of the Closed-Loop Control (CLC), also
      known as Artificial Pancreas (AP) named Tandem t:slim X2 with Control-IQ Technology and
      assess usability in a supervised setting in a controlled environment compared with
      state-of-the-art Sensor-Augmented Pump (SAP) therapy for the treatment of type 1 diabetes
      (T1D) in adolescents.
    
  